If a single integrated cloud-based system existed for labelling pharmaceutical products, it could provide complete transparency and traceability across the entire industry. Despite the data challenge, Kallik believes companies can be aiming towards implementing cloud-based systems.

Featured in PMPS magazine, Connecting the Disconnected which was created by Graham Francis, explains what currently limits labelling traceability, the impact the lack of transparency has on traceability and single integrated cloud-based solutions.

Read more here. (Pages 40-41)

About PMPS

Pharmaceutical Manufacturing and Packing Sourcer (PMPS) is a specialist journal designed to provide worldwide coverage of a range of topics relating to the pharmaceutical manufacturing and packaging sector.

Published quarterly, the journal functions as a platform of communication and information-sharing for executive and strategic decision-makers within the industry, identifying new trends and marketing opportunities, as well as highlighting the latest innovations in this dynamic environment. PMPS is specifically designed to interest those in the pharma, biotech, nutritional, and medical device industries who are actively seeking to source services for improved efficiency in what is an increasingly competitive market.


Kallik to sponsor Pharmaceutical and Device Packaging and Labelling in September.

Kallik is set to sponsor and speak at Pharmaceutical and Device Packaging and Labelling (PHPL) conference in Munich on 10th and 11th September 2019.

Ashley Goldie, Kallik’s Managing Director will be presenting at the event, which attracts pharma and biotech experts from across Europe.

Pharma Packaging and Labelling Europe conference already has over 150 confirmed attendees, with an excess of 25 speakers, such as Matthias Korbl of Seigfried Pharma and Dirk Duppré of Medical Devices LivaNova, as well as over 15 exhibitors.

This year PDPL will be discussing some of the most pressing issues affecting commercial packaging and labelling within pharma, such as E-labels, Secure packaging, Artwork processes, Smart packaging, Tamper Evident Labels, and Anti-Counterfeiting Solutions.

PDPL has proven itself to be a popular choice for key industry figures to discover new solutions and generate discussion amongst their peers, with 75 per cent of attendees being at or above directorial levels.

With Kallik’s recent launch of AMS360 Release 6,  the conference will be a great opportunity to discuss its unique single cloud-based platform capabilities and highlight its ability to aid compliance to new legislation, such as the EU MDR.

You can register for the event here – https://www.arena-international.com/pharmapackagingeurope/register/

Tags: labelling, packaging, pharmaceuticals

Tamworth, UK – 13 June 2019 – Global provider of labelling and artwork
management solutions, Kallik, is launching an update to its AMS360 solution – its
Release 6, transforming the experience of the business user, whilst defining new
benchmarks for speed, accuracy, and efficiency of global labelling and artwork

More complex and competitive marketplaces, weaker margins, and increasing
enforcement of regulations, place ever-increasing challenges on managing larger
and more diverse product portfolios across ever-developing channels.
Being able to prove compliance is paramount within labelling. With Release 6, not
only are diverse product portfolios centralised in one single cloud-based platform,
achieving transparency across all channels, but compliance can be demonstrated
within seconds.

For the first time, global organisations are able to derive printed and electronic
labelling from one integrated solution. Release 6 is driven by the latest web
technologies, maximising user experience whilst providing greater data oversight
and transparency.

A brand-new user interface simplifies content collation whilst providing greater
visibility of assigned tasks and progress. Responding to demands for more tailored
products and local market regulations, the solution delivers greater volumes of
components that can be assigned to a labelling project without any degradation in

Ashley Goldie, Managing Director of Kallik, said: “Global organisations now have the
ability to source an integrated solution which provides complete oversight and data
transparency across both printed and electronic labelling. Not only is a faster user
experience being offered with this update, it also brings new productivity gains to
activities such as data capture, content collation and impact analysis.

“Release 6 of AMS360 redefines the benchmarks for accuracy and efficiency of
global labelling. With organisations seeking to derive greater efficiencies whilst
continuing to satisfy increasingly stringent legislation and regulation, we truly believe
it is a very needed and necessary solution.”

Release 6 adheres to these principles by eliminating costly and inefficient processes,
reducing risk of non-compliance, enabling optimal use of labelling resources across
the entire global organisation.

To find out more information about Kallik’s Release 6, and schedule a demo, visit https://kallik.com/labelling-and-artwork-management-products/ams360-release-6/

For more information about Kallik, please visit http://www.kallik.com

– Ends –

About Kallik
Kallik is a global provider of labelling and artwork management solutions for
regulated markets such as the pharmaceutical, medical devices, cosmetics and
chemicals industries. By centralising messaging content, Kallik enables large
national and international organisations – often with thousands of products – to
produce accurate, print-ready artwork for their packaging and labelling in seconds.
Kallik stores all content – text, symbols and logos – as structured data, and manage
it in a streamlined way. As a result, amending artwork in line with new market-
specific requirements is quick and easy – even if multiple product lines are affected,
across multiple markets and in multiple languages.

Press contact
Please feel free to reach out to our PR team via email:
David Callaghan
PR contact
Phone: +44 (0)121 389 2499
Email: [email protected]

Graham Francis
Channel Marketing Manager
Phone: +44 1827 318100
Email: [email protected]

Last week’s UDIs and Traceability for Medical Devices conference in Amsterdam highlighted some of the key developments in UDI implementation and alignment across the regulatory, supply chain and customer environments as we move one year closer to the EU MDR. We had the opportunity to hear from and engage with key speakers and delegates from some of the leading medical device companies, as well as our own CEO, Neil Gleghorn who delivered a very well received presentation on how embracing UDI can create a more connected digital labelling enterprise.

As UDI regulations begin to mature across the EU and US, countries including India, China and South Korea are beginning to adopt a similar strategy. From this, it is highly likely that there will need to be multiple iterations of labelling for the same products in order to meet these evolving requirements. Healthcare providers (including the NHS) will also be looking for specific labelling content to meet their individual procurement and supply chain requirements.

Dennis Black, Director of e-Business Solutions Group, BD provided some interesting insights around this. Dennis believes that regulators and providers should work towards a global, harmonised approach but recognises that this may not be entirely possible. The impact of not doing so is the cost and the risk of errors being introduced each time a market specific or provider specific requirement needs to be captured on the label. The ultimate risks being non-compliance with regulatory requirements with the result of losing valuable contracts with healthcare providers.

A recent study carried out by McKinsey & Co. demonstrates just what can be achieved by having better-connected systems and processes. These include reduced time to market and inventory costs of between 20-50% and an increase of 45-55% in productivity. It must be advised that changes to labelling alone will not deliver these figures, but without addressing the challenges around disconnected labelling systems and processes, we predict it’s likely that these figures would diminish.

So, how does this impact medical device labelling? Organisations must be able to adapt quickly to labelling changes driven by the evolving maturity of UDI. This will ensure they don’t lose out to competitors that may have more dynamic systems in place. The FDA acknowledged that they are now sharpening their focus on data quality, and specifically, addressing the need for accurate labelling data uploads to their UDI database (GUDID). This is in the interest of ensuring that patients, having received an implantable, or who are using medical devices, receive accurate and transparent information relating to their use, manufacture and authenticity. This applies equally, whether reading from a printed label, manufacturer’s webpage or searching the GUDID.

A subject that was widely discussed at the conference was that of ‘Basic UDI-DI’. As part of the MDR, a Basic UDI-DI is being introduced. This refers to the relationship between what is a family of products that may otherwise appear to be unique individual products e.g. if one product in a family has manufacturing defects and needs to be recalled, the Basic UDI-DI shows this relationship. The basic UDI-DI itself doesn’t appear on the label but an organisation must be able to identify all other related products as a result of querying the UDI on the label via the EU UDI database (EUDAMED). This relationship is something that medical device manufacturers will need to capture and make available for on-demand searches by patients, providers and notified bodies with the ask made much simpler by connecting previously disparate labelling processes.

The challenge for many organisations is that they lack the tools, systems and processes to be able to dynamically identify and update product labelling in suitable timescales. All, of course, whilst retaining fluidity, compliance and avoiding disruption of supply chains.

This is where Kallik’s ‘where used’ function can really help. At the press of a button, it allows any authorised user to quickly locate one or more product families from one single identifier (i.e. the Basic UDI-DI).

Are you interested in finding out how Kallik can prepare your organisation for the upcoming EU MDR as well as simplify compliance with the Basic UDI-DI? Get in touch with our labelling and artwork management experts here and/or visit our resources page for more insights.

Founded in 1924, House of Cheatham is one of the oldest continuing manufacturers of personal and beauty care products in America. But that does not come without its challenges. As a company, House of Cheatham were in desperate need of a cloud-based labelling and artwork management solution, to respond to an exponential increase in global regulatory requirements.


Upon choosing Kallik, House of Cheatham are seeing an 80% reduction in speed to market, with 10 weeks taken out of the process, and an average of 6-fold increase in the number of artworks created per year compared to the previous solution.

House of Cheatham’s Director of Enterprise Development, Jeff Carson, talks through the problems he has faced and solutions he has chosen, with Kallik’s AMS180 vastly improving the company’s artwork production.

What were the challenges you were experiencing in labelling data and artwork production?

Maintaining the latest versions of artwork files was becoming an increasingly serious challenge. We were missing key opportunities as a business every time a label change was required. A typical example we were experiencing was up to nine amends per artwork were needed before files could be approved and released to print. It was clear our data files were disjointed from the process and we really found it difficult as a business to keep up with the pace of change.

How did you look to resolve this ongoing issue?

We knew it was of paramount importance that we acted quickly and efficiently to adopt a solution, to not only stay compliant with new regulatory requirements but to remain competitive in the marketplace. We looked at several options but Kallik AMS180 was by far the most efficient and impressive choice. It was the perfect solution to minimise capital outlay on in-house IT resources and was the best fit for the business.

Since choosing Kallik, talk us through the impact it has had on your business?

It’s had a profound effect. The Kallik team immediately understood the requirements of House of Cheatham as a small to medium business and the ROI from the scalability and flexibility of the solution was remarkable; it gave us the exact functionality we needed. We knew when making the decision that Kallik were at least two years ahead of their nearest competitor using cloud technology.

What have been the key changes and benefits of using Kallik AMS360?

In the first year of implementing the solution, we processed 140 new artworks. This is in comparison to creating just 24 per annum before Kallik, which is obviously a huge and impressive increase. Following on from that, in our second year we increased this number to 400 with no additional resources, but in turn increased the accuracy of our artwork production and have taken significant costs out of the process. This is 17 times more artwork production capacity with zero increase in resources, which is a fantastic achievement.

When looking to create new artwork versions, we now as a company have complete confidence in creation processes and selecting the latest approved version to initiate projects. The correct version of the artwork is now always sent to the print supplier base.

How have House of Cheatham’s employees adapted to using Kallik’s cloud-based labelling and artwork management solution?

Staff now have more time freed up which allows them to work on additional added-value projects, and this has seen our output increasing, but with the same number of staff.

The solution’s benefit has been felt across the whole business, with our marketing project managers key advocates of Kallik’s AMS180 as they’re now able to drive projects with 100 per cent accountability.

With this solution in place, do you have plans to expand your process or business?

Absolutely. House of Cheatham is expanding the use of Kallik’s solution by using its Asset manager as a way of controlling and versioning its ingredient declarations. With such a huge, positive impact on labelling inventory and reducing stock levels, new labels can now be produced to an agreed critical path to ensure on-time delivery. We couldn’t be happier to have chosen Kallik and will look to have plans in place to progressing additional capabilities soon.

For more information on House of Cheatham, visit their website: www.houseofcheatham.com

Download the House of Cheatham Case Study here.

Tamworth, UK – 10 April 2018 – Global provider of labelling and artwork management solutions, Kallik, are delighted to announce Ashley Goldie as its new Managing Director.


Ashley’s new position is in line with the company’s strategy of organic growth, which sees experienced employees from within continue to progress, innovate and provide a committed service to Kallik’s target markets. His appointment comes at a time of development for Kallik, who are looking to expand its premises this year and engage in a recruitment drive to source employees who have the same ethos and industry focus as the solutions provider.

With nearly 30 years working internationally with major life science and branded organisations, Ashley has spent the last eight years as Kallik’s Sales and Marketing Director. Within that period, he has quadrupled turnover, gained invaluable insight into labelling and customer requirements and successfully positioned Kallik as a key leading provider in highly regulated sectors – Pharmaceutical, Medical Device, Cosmetic and Chemical.

“I am delighted to be given this opportunity,” he comments. “I look forward to the challenge of overcoming the transformational differences these heavily regulated industries are facing by delivering products of superior value, quality and performance whilst staying compliant across highly competitive global markets.

One of Ashley’s first actions, was to announce two further promotions within the company. Dave Tarbuck, who has been with Kallik over eight years, has been named as the new Global Client Services Director and Rob Woodall has been appointed Technical Director. Rob previously fulfilled the role of Lead Architect, having been with the company since 2007.

Ashley continues: “Both will bring invaluable know-how, expertise and commitment to their respective roles and exemplify Kallik’s process of internal growth. We aim as a team and company to continue to stay innovative and forward-thinking as the leading global labelling content management and artwork generation solutions provider for regulated industries.”

Ashley will look to build upon the team’s experience and knowledge, offering guidance and direction to the company’s focus. Building robust, scalable solutions that will satisfy the rigorous demands of global corporations in the heavily relegated sectors.

These solutions streamline labelling content into a seamless artwork process, which helps businesses to remove duplication, track content and efficiently change messaging to respond to new markets and regulatory changes – in print and online.

For more information about Kallik, please visit http://www.kallik.com/

About Kallik

Kallik is a global provider of labelling and artwork management solutions for regulated markets such as the pharmaceutical, medical devices, cosmetics and chemicals industries. By centralising messaging content, Kallik enables large national and international organisations – often with thousands of products – to produce accurate, print-ready artwork for their packaging and labelling in seconds. Kallik stores all content – text, symbols and logos – as structured data, and manages it in a streamlined way. As a result, amending artwork in line with new market-specific requirements is quick and easy – even if multiple product lines are affected, across multiple markets and in multiple languages. For more information visit: http://www.kallik.com/

Press contact
Please feel free to reach out to our PR team via email:

David Callaghan
PR contact
Phone: +44 (0)121 389 2499
Email: [email protected]

Graham Francis
Channel Marketing Manager
Phone: +44 1827 318100
Email: [email protected]

By Graham Francis, Channel Marketing Manager, Kallik Ltd.


In my last blog, I talked about how organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.

Transforming existing paper-based legacy artwork management systems and processes to a new digitally-driven environment are two concepts that can, in fact, work together to help highly regulated industries reduce the risk of non-compliance and costly product recalls. Firstly, all parties or stakeholders, including regulatory, marketing and manufacturing must have access to the same system that masters the content – this means they must have access to the correct level of permissions in order to edit, modify and review the labelling content as needed. Secondly, when much of the labelling content is held in a range of documents, emails, PDFs and printed documents, it can become difficult to construct, deconstruct and reuse labelling content. These organisational challenges, therefore, need to be overcome, calling for the digitisation of all labelling assets.

Labelling and artwork processes have tended to be seen as more of a cost overhead rather than a core business activity. This can lead to systematic failures due to a lack of clear ownership, loosely defined decision-making processes and too much reliance on ‘tribal knowledge’. In other cases, need to make repetitive ‘low-level’ decisions manually, where these could otherwise be easily automated can lead to fatigue and unnecessary errors. The end result can be costly product recalls potential fines and brand damage through non-compliance.

This is where the ‘business rules’ approach comes in – managing the decision-making process as a set of business rules allows for more responsive changes or additions to processes as this can be undertaken by business users as opposed to writing code. Whilst we could choose to implement a standalone business rules engine to automate many of the existing manual driven processes that often exist, we would still be left with the challenge of discovering and extracting the source content needed for each label variant. The way we can overcome this is by digitising and versioning each of our labelling assets (logos, warning statements, images, etc.) and ensure that these are easily discoverable. We can then configure our business rules engine to find, and subsequently populate, each of the variable fields we may need on our labels depending on where the product is going to be sold and which local market legislation needs to be adhered to.

Much of the medical device industry is quite rightly focused on understanding the impact of the legislative framework and being in a state of readiness to populate the EU equivalent of the GUDID, this being EUDAMED (European Database on Medical Devices) by May 2020. In addition, implementing the upcoming European Unique Device Identifier will require considerable investment and strategic planning for many organisations, so now is a good time to consider options for process re-engineering.

At Kallik, we see the EU MDR as an opportunity for organisations to review the effectiveness of their current labelling and artwork processes and how digitising supply chains can strengthen compliance and simplify evolution toward e-Labelling. Securely managing all product and prescribing-related information in a single version controlled environment enables unlimited composition, re-use and printing of any type of label anywhere. Furthermore, your labelling becomes ‘channel agnostic’, that is it can be delivered through multiple channels (web, mobile, social) as well as via the more traditional paper-based means of presentation.

Adopting labelling digitisation enables more robust regulatory submissions and ultimately increases the transparency of enterprise-wide review and approval processes. This can simplify the integration of extended supply chains and shorten time to market during periods of mergers and acquisitions.

Want to find out more? Join us at UDIs & Traceability for Medical Devices on 17th May at 11.40am. Kallik Founder and CEO, Neil Gleghorn, will be discussing why connected labelling systems and processes are essential prerequisites to minimising disruption and enabling greater productivity across extended supply chains, ensuring enhanced compliance with MDR. Book a meeting.

The Kallik team will also be on-hand to discuss how you can embrace digital technology to transform your labelling and artwork processes, achieve readiness for re-labelling and increase global supply chain collaboration. If you’d like to find out more, get in touch with the Kallik team.

Take a look at our recent White papers.

By Graham Francis, Channel Marketing Manager, Kallik Ltd.


As March approaches, there’s much that those working within heavily regulated industries need to be focusing on for the rest of the year to stay compliant, take cost out of supply chain operations and increase their speed to market.

At Kallik, we spend a lot of time researching how we can help our customers achieve these goals by making the best use of emerging technologies. We’ve previously discussed ‘Connecting the Disconnected’, Industry 4.0, and Digital Transformation – what each of these approaches has in common is the underlying use of digital technology to make it easier to create, share, approve and print, labelling and artwork content. We’ve seen organisations previously hampered by document-centric and paper-based process released into the 21st century by adopting this approach, achieving impressive gains in productivity and quality to boot.

Whilst we’re delighted to have been part of this revolution, we believe there is a lot more to come. If we look across industries such as finance, banking, insurance and retail, we’ve seen an explosion in the services and products available, much of it driven by competition and consumer demand. This has resulted in a huge number of choices available underpinned by hugely complex business decisions and massive amounts of data – which some would call Big Data.

Many of these industries have responded to this opportunity by automating their manual, repetitive and time-consuming decisions by implementing business rules technologies and building rule sets that map to organisational processes. This approach delivers greater consistency, eliminates costly errors and vastly increases productivity. Now becoming mature, robust and well-proven as increasingly well understood throughout the industry, we believe that business rules engines have a significant role to play in the labelling and artwork management arena. We believe this to be the ‘next big thing’ for labelling and artwork and have just published a brand new white paper to help share our vision – A Rules-Based Approach to Labelling and Artwork Management.

Download your copy of the paper here.

If you’d like to learn more about how Kallik can help you innovate across your labelling supply chain, you can get in touch with the team here.


Firstly, Kallik would like to wish all of its customers a very happy and prosperous New Year and would like to thank you for your continued business and support.  We would also like to extend our greetings to our technology partners and those who are seeking to transform their labelling and artwork processes going forward but have yet to reach a decision on who to choose as their industry partner.

Looking ahead, 2018 is going to be an exciting and eventful year as we begin to see the effect of new legislation and regulation taking shape across several continents.  Further extension of the UDI Final Rule will see this impacting hundred of thousands of devices not previously affected.  By the end of September this year, all packaging and labelling associated with Class I medical devices sold into the US must bear a UDI as the FDA moves closer towards completion of its UDI roll-out across the industry.

Continuing with the UDI theme, 2018 will see Europe moving closer to the date when the new Medical Device Regulations (MDR) will replace the existing Medical Device Directive (MDD).  This now is just over two years out.  With much of the impacted industry focusing on capturing and compiling the content required for submission to the EU equivalent of the GUDID (EUDAMED), the additional requirement for publishing all labelling content electronically (including eIFU’s and labelling content being published on manufacturer’s websites) has not been given the attention we believe it requires.  This is one area where you can expect to see new thought leadership from ourselves as we move further into the year.  Please feel free to visit our blog pages where we’ll be posting our first post on this topic later this month with subsequent articles and papers to follow.

Turning from Medical Device to Pharmaceuticals and serialisation, the previously announced delayed enforcement of the US Drug Supply Chain Security Act (DSCSA) by one year to November 2018 acknowledged that some pharmaceutical manufacturers along with their contract manufacturers were not in a state of readiness to comply.  It is less likely that the deadline will be extended further, so the pressure is increasing to ensure all impacted medicines will carry a product identifier on their labelling and packaging.  Focusing back on the EU, the deadline for complying with the Falsified Medicines Directive (FMD) is approaching fast with this currently set for February 2019.  Many of the challenges faced by European based manufacturers are expected to be similar to those encountered by their US counterparts, including the need for a unique serial number to be made present on all packaging and labelling.

As both the chemicals and cosmetics industries continue to seek further growth through gaining entry into new emerging markets, compliance with local labelling legislation is a must in order to prevent delays in satisfying import controls that could otherwise see stock being impounded for months.  Here again, clear corporate oversight with an ability to capture and tailor product labelling content to satisfy local markets is paramount.

So, what can you expect from Kallik this year?  Well, this year will see us further strengthen our enterprise-wide labelling solution for heavily regulated industries.  Some of these enhancements will make it easier for our customers to encapsulate all their labelling and artwork processes in one single solution across all types of print and packaging.  This will give greater visibility, control and corporate oversight both in-house and out across extended supply chains.  Other enhancements will simplify the roles of all those involved in capturing and collating content, further de-risking potential non-compliance whilst at the same time, increasing productivity.  We’re looking forward to sharing some of these enhancements with you very soon, so please check back with us here on a regular basis for further updates.

Finally, once again, all of us here would like to wish you all continued success both throughout 2018 and beyond and we look forward to continuing to develop both existing and new relationships across the industry.

The Kallik Team


By Graham Francis, Channel Marketing Manager, Kallik Ltd.


Last month’s Supply Chain Innovation Summit confirmed that there is a good deal of activity across the pharma industry right now to try to improve the efficiency of supply chain operations. Much of this is being driven by the need to improve levels of productivity and quality, but there are other drivers too; such as minimising inventory and responding to an increased demand for personalised medicines. Research into smart packaging being carried out by the Medicines Manufacturing Industry Partnership (MMIP) is also helping the industry develop its technology roadmap. You could say much of what was discussed was around ‘connecting the disconnected.’

In terms of quality, we heard from CMAC that first time manufacturing across the industry is generally very poor – typically 60,000 defects per million which equates to just over 3-sigma. The effect of this being an estimated 25% of manufacturing resource being engaged in quality activities, with much of the pharma industry using ‘batch’ as opposed to ‘continuous’ manufacturing methods. Whilst manufacturing in the batch was probably the best approach for blockbuster drugs, it’s not seen as the best fit for producing more niche, personalised medicines. CMAC’s research in this area suggests a shift towards continuous manufacturing could deliver an 86% reduction in working capital across the industry.

This shift from ‘make from stock’ to ‘make to order’ is something that the automotive industry has been embracing for longer than is often thought. In fact, Toyota introduced this methodology back in 1953 and it’s what we now often refer to as Industry 4.0. Back then, it was the post-war scarcity of resources that drove this approach. Whilst today’s drivers are different, the adoption of lean manufacturing processes across the industry is what enables personal choice without the need for billions of dollars of inventory.

Of course, manufacturing is just one element of the global supply chain. We also heard from a number of suppliers offering broader supply chain solutions that could help the industry meet EU GDP guidelines. These seek to address challenges around logistics, environmental and temperature monitoring as well as track and trace. One pharma company having put such systems and processes in place shared with us how this helped to identify and eliminate sources of temperature violations. These saving weeks of investigative and reporting effort in locating the source of the problem.

Moving on to look at some other strategies embraced across pharma, agrochemical and cosmetics industries, we heard how Leo Pharma, Novartis, Syngenta and COTY had introduced greater accountability across all forecasting activities. This resulted in reduced stock-outs, cut inventory and improve traceability. Despite operating across different markets, the drive towards having one single version of the truth, greater process transparency and increased levels of personal accountability were common themes that delivered results.

So, how does this align with our vision for ‘connecting the disconnected’ when it comes to labelling and artwork? Actually, many of the concepts discussed at the summit apply equally to labelling supply chains as they do product. In fact, a product doesn’t become a product until it carries a label. That’s one of the reasons why we believe enterprise-wide engagement is essential in getting label content right the first time. Encouraging greater transparency, supporting personalisation through late-stage printing while adopting cloud-based technologies to achieve higher levels of collaboration are also concepts we support. It’s great to see the industry embarking on new initiatives in these areas and it’s something we will continue to support and encourage across all regulated industries.

If you’d like to learn more about how Kallik can help you innovate across your labelling supply chain, please feel free to leave a reply below or get in contact with us here.